Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We evaluated the specific causes of death and their associated risk factors in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: We used data from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study (n = 14,671), a cardiovascular (CV) safety trial adding sitagliptin versus placebo to usual care in patients with type 2 diabetes and ASCVD (median follow-up 3 years). An independent committee blinded to treatment assignment adjudicated each cause of death. Cox proportional hazards models were used to identify risk factors associated with each outcome. RESULTS: A total of 1,084 deaths were adjudicated as the following: 530 CV (1.2/100 patient-years [PY], 49% of deaths), 338 non-CV (0.77/100 PY, 31% of deaths), and 216 unknown (0.49/100 PY, 20% of deaths). The most common CV death was sudden death (n = 145, 27% of CV death) followed by acute myocardial infarction (MI)/stroke (n = 113 [MI n = 48, stroke n = 65], 21% of CV death) and heart failure (HF) (n = 63, 12% of CV death). The most common non-CV death was malignancy (n = 154, 46% of non-CV death). The risk of specific CV death subcategories was lower among patients with no baseline history of HF, including sudden death (hazard ratio [HR] 0.4; P = 0.0036), MI/stroke death (HR 0.47; P = 0.049), and HF death (HR 0.29; P = 0.0057). CONCLUSIONS: In this analysis of a contemporary cohort of patients with diabetes and ASCVD, sudden death was the most common subcategory of CV death. HF prevention may represent an avenue to reduce the risk of specific CV death subcategories.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial, which recruited ~1200 persons who were either hospitalized with HF or were recently discharged following hospitalization for HF, and all of whom had T2D, a mixed SGLT1/2 inhibitor sotagliflozin also significantly reduced the primary endpoint of total HF hospit”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [653]
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“For CV death, a further sensitivity analysis that used the Fine-Graymethod (11) accounted for the competing risk of non-CV and unknown causes of death, with results reported on the basis of subdistributional hazard functions.”
MethodEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 1×
“In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study (17), sudden death was the most commonly adjudicated cause of CV death (68 of 227 [29.”
BackgroundSelf-citationTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationStandards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,465
Excess Mortality among Persons with Type 2 Diabetes
Tancredi, M., Rosengren, A., Svensson, A.-M., Kosiborod, M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Clements, M., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 996
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Research works printed but not linked: 1
- International Diabetes Federation, 2015, IDF Diabetes Atlas
Cited by
Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T. B., Schnell, O., Standl, E., & Beulens, J. W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319878371 · Cited by 1,009
“After sudden cardiac death, which represents the largest subcategory of cardiovascular death in subjects with T2DM and established ASCVD (27% of cardiovascular deaths), acute myocardial infarction (MI), along with stroke, represents the second most lethal complication (21%).(11) Several follow-up studies came to the s…”
BackgroundSelf-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
The global epidemics of diabetes in the 21st century: Current situation and perspectives
Standl, E., Khunti, K., Hansen, T. B., & Schnell, O. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319881021 · Cited by 497
“as studied in the TECOS trial, more than 50% of all deaths are due to cardiovascular causes, with sudden death being the most common cause, followed by combined death from myocardial infarction or stroke, and death from heart failure.(36) Particularly high death rates are unfortunately still reported for young-onset t…”
BackgroundSelf-citationCardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 110
Self-citationRubio, J. A., Jiménez, S., & Lázaro‐Martínez, J. L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9093009 · Cited by 139
“with and without DFD [9], as well as the high frequency of death due to cardiovascular disease in cardiovascular safety studies [26], indicate that cardiovascular disease is the leading cause of death in diabetic patients.”
BackgroundAbraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.002 · Cited by 123
Coopmans, C., Zhou, T. L., Henry, R. M. A., Heijman, J., Schaper, N. C., Koster, A., Schram, M. T., van der Kallen, C. J. H., Wesselius, A., den Engelsman, R. J. A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2367 · Cited by 93
Stress Testing Versus CT Angiography in Patients With Diabetes and Suspected Coronary Artery Disease
Sharma, A., Coles, A., Sekaran, N. K., Pagidipati, N. J., Lu, M. T., Mark, D. B., Lee, K. L., Al-Khalidi, H. R., Hoffmann, U., & Douglas, P. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.056 · Cited by 72
“Among patients across the spectrum of glycemic disorder, including those with pre-diabetes (19) and those with diabetes and established CV disease (20), non-CV death forms a large burden of mortality.”
BackgroundSelf-citationKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
Papadopoulou, E., Loutradis, C., Tzatzagou, G., Kotsa, K., Zografou, I., Minopoulou, I., Theodorakopoulou, M. P., Τσάπας, Α., Karagiannis, A. I., & Sarafidis, P. A. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002690 · Cited by 74
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2018 · Cited by 70
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N., Skra, J., Valensi, P., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Self-citationKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
Ahmad, A., Lim, L., Morieri, M. L., Tam, C. H. T., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2024) · Communications Medicine · doi:10.1038/s43856-023-00429-z · Cited by 82
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 52
“Background Coronary heart disease, cerebrovascular disease and peripheral arterial disease of atherosclerotic origin, collectively termed atherosclerotic cardiovascular disease (ASCVD), are the major cause of mortality in patients with diabetes mellitus [1, 2].”
BackgroundSelf-citationSharma, A., Vaduganathan, M., Ferreira, J. P., Liu, Y., Bakris, G. L., Cannon, C. P., White, W. B., & Zannad, F. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012797 · Cited by 40
Self-citationTREM-1; Is It a Pivotal Target for Cardiovascular Diseases?
Kouassi, K. T., Gunasekar, P., Agrawal, D. K., & Jadhav, G. P. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5030045 · Cited by 35
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Sharma, A., Cooper, L. B., Fiuzat, M., Mentz, R. J., Ferreira, J. P., Butler, J., FITCHETT, D. H., Moses, A. C., O’Connor, C. J., & Zannad, F. M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.020 · Cited by 29
Self-citationVerma, S., Sharma, A., Zinman, B., Ofstad, A. P., FITCHETT, D. H., Brueckmann, M., Wanner, C., Zwiener, I., George, J. T., Inzucchi, S. E., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14015 · Cited by 28
“The risk of developing HF is greatly increased in patients with T2D.3,4 Furthermore, HF death contributes to a large burden of overall cause of death among patients with T2D with established ASCVD.14 Moreover, the risk of HF seems to persist, although slightly decreased, despite control of multiple CV risk factors, su…”
BackgroundSelf-citationCoiro, S., Girerd, N., Sharma, A., Rossignol, P., Tritto, I., Pitt, B., Pfeffer, M. A., McMurray, J. J. V., Ambrosio, G., Dickstein, K., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1541 · Cited by 27
Self-citationArtificial Intelligence-Based Digital Biomarkers for Type 2 Diabetes: A Review
Jabara, M., Köse, O., Perlman, G., Corcos, S., Pelletier, M.-A., Possik, E., Tsoukas, M. A., & Sharma, A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.07.028 · Cited by 40
Self-citationPredictors of heart failure development in type 2 diabetes: a practical approach
Verma, S., Sharma, A., Kanumilli, N., & Butler, J. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000647 · Cited by 26
Self-citationWang, J., Wu, Y., Shin, S., Tien, K., Chin, M.-C., & Hwu, C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.06.017 · Cited by 20
Sharma, A., Inzucchi, S. E., Testani, J. M., Ofstad, A. P., Fitchett, D., Mattheus, M., Verma, S., Zannad, F. M., Wanner, C., & Kraus, B. J. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14601 · Cited by 24
“24,25 It should be noted, however, that this was based on the multivariable model including the combination of all baseline factors presented.”
BackgroundSelf-citationSharma, A., Aziz, H., Verma, S., Abramson, B. L., Choi, R., Chua, G. L., Connelly, K. A., Honos, G. N., Mancini, G. B. J., Ramer, S. A., et al. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000892 · Cited by 19
Self-citationNiazmand, S., Mirzaei, M., Hosseinian, S., Khazdair, M. R., Shabgah, A. G., Baghcheghi, Y., & Hedayati‐Moghadam, M. (2021) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2021-0142 · Cited by 26
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes
Sharma, A., Ofstad, A. P., Ahmad, T., Zinman, B., Zwiener, I., FITCHETT, D. H., Wanner, C., George, J. T., Hantel, S., Desai, N. R., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.03.003 · Cited by 21
Self-citationObesity and its management in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 21
Self-citationCardiovascular autonomic neuropathy in type 2 diabetic patients
Breder, I. S. S., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.56 · Cited by 16
Zhang, A., Luo, X., Meng, H., Kang, J., Qin, G., Chen, Y., & Zhang, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.604250 · Cited by 16
Felício, J. S., Koury, C. C., Zahalan, N. A., Resende, F. D. S., de Lemos, M. N., Pinto, R. J. D. M. C., Neto, N. J. K. D. S., de Franco, I. I. F., de Oliveira, M. C. N. I., de Alcântara, A. L., et al. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119829385 · Cited by 15
Alkhezi, O. S., Alsuhaibani, H. A., Alhadyab, A. A., AlFaifi, M., Alomrani, B., Aldossary, A., & Alfayez, O. M. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.04.005 · Cited by 14
Iglay, K., Hannachi, H., Engel, S. S., Li, X., O’Connell, D., Moore, L. M., & Rajpathak, S. N. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1895736 · Cited by 12
Holstein, A., Titze, U., & Heß, C. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0752-0028 · Cited by 14
Papadopoulou, E., Theodorakopoulou, M. P., Loutradis, C., Tzanis, G. S., Tzatzagou, G., Kotsa, K., Zografou, I., Τσάπας, Α., Karagiannis, A. I., & Sarafidis, P. A. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa207 · Cited by 12
Kwiendacz, H., Nabrdalik, K., Adamczyk, P., Moczulski, D. K., Moczulska, H., Trautsolt, W., Górczyńska-Kosiorz, S. B., Grzeszczak, W., & Gumprecht, J. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2019.0066 · Cited by 11
“3, p = 0.6) nor with eGFR reflecting the CKD stage (Tab.”
BackgroundInfluentialOscillatory pattern of glycemic control in patients with diabetes mellitus
Vásquez-Muñoz, M., Arce‐Álvarez, A., von Igel, M., Véliz, C. V., Gonzalo Ruiz-Esquide, S., Ramírez‐Campillo, R., Álvarez, C., Ramírez‐Vélez, R., Crespo, F., Izquierdo, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84822-5 · Cited by 12
Badacz, R., Przewłocki, T., Pieniążek, P., Rosławiecka, A., Kleczyński, P., Legutko, J., Zmudka, K. F., & Kabłak-Ziembicka, A. (2022) · Molecules · doi:10.3390/molecules27082472 · Cited by 11
“3%), heart failure (12%), and MI (9%) [4].”
BackgroundSharma, A., Wu, J., Ezekowitz, J. A., Felker, G. M., Udell, J. A., Heidenreich, P. A., Fonarow, G. C., Mahaffey, K. W., Hernandez, A. F., & DeVore, A. D. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12528 · Cited by 11
Self-citationMarx, N., Rydén, L., Brosius, F. C., Ceriello, A., Cheung, M., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108092 · Cited by 10
Self-citationSumin, A. N., Bezdenezhnykh, N. A., Bezdenezhnykh, A. V., & Artamonova, G. V. (2021) · Diagnostics · doi:10.3390/diagnostics11030474 · Cited by 11
Monocyte CD36 expression associates with atherosclerotic burden in diabetes mellitus
Chandran, J., Wadhwa, N., Madhu, S. V., Kumar, R., & Sharma, S. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108156 · Cited by 9
Standl, E., & Schnell, O. (2025) · Cells · doi:10.3390/cells14080564 · Cited by 10
“…without [9], with incident all-cause mortality also relatively increasing because of the increasing number of cancer deaths [9]. diabetes are attributable to Some 50% of all non-cardiovascular deaths in contemporary cohorts with diabetes are a tt ributable to malignancies [10]. malignancies [10].”
Self-citationScreening cardiovascular risk factors of diabetes patients in the primary diabetes clinics
An, L., Wang, Y., Cao, C., Chen, T., Zhang, Y., Chen, L., Ren, S., Tang, M., Ma, F., Li, X., et al. (2021) · Medicine · doi:10.1097/md.0000000000026722 · Cited by 6
Garcia, R., Schröder, L. C., Tavernier, M., Gand, E., Keizer, J. D., Holkeri, A., Eranti, A., Bidegain, N., Alos, B., Junttila, J. M., et al. (2024) · Diabetologia · doi:10.1007/s00125-023-06074-4 · Cited by 9
“Diabetes illustrates this situation well because of the high non-SCD risk [10, 11].”
Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction
Sharma, A., Lam, C. S. P., Tay, W. T., Yap, J. J. L., MacDonald, M. R., Razaghizad, A., Cooper, L. B., O’Connor, C. J., Whellan, D. J., Anand, I. S., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.05.002 · Cited by 6
“Similarly, the Trial Evaluating Cardiovascular Outcomes with Sitagliptin trial (N 1⁄4 14,671) recorded 1,084 deaths, of which 49% (n 1⁄4 530) were CV, 31% (n 1⁄4 338) were non-CV, and 20% (n 1⁄4 216) were unknown.(4) Our analysis adds to these findings by demonstrating the presence of ethnic variations with respect to…”
Self-citationAsymptomatic Peripheral Arterial Disease Among Jordanian Patients With Diabetic Foot Ulcer
Abu-Jableh, W., Younis, A. T., Hjazeen, A. A., Mashaqbeh, E., & Al-Sharif, E. (2024) · Cureus · doi:10.7759/cureus.73722 · Cited by 5
Loutradis, C., Schoina, M., Dimitroulas, T., Doumas, M. N., Garyfallos, A., Karagiannis, A. I., Papagianni, A. A., & Sarafidis, P. A. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14089 · Cited by 4
Ahmad, A., Lim, L., Morieri, M. L., Tam, C., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2929263/v1 · Cited by 5
Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure
Sharma, A., & Ezekowitz, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.012 · Cited by 4
Self-citationKoziolova, N. A., Polyanskaya, Е. А., & Миронова, С. (2022) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2022-3-4-7-24 · Cited by 6
Sharma, A., Butler, J., Zieroth, S. R., Giannetti, N., & Verma, S. (2019) · Diabetic Medicine · doi:10.1111/dme.14140 · Cited by 4
Self-citationAhmad, A., Lim, L., Morieri, M. L., Tam, C. H. T., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2023) · medRxiv · doi:10.1101/2023.04.26.23289177 · Cited by 4
Dynamic circadian fluctuations of glycemia in patients with type 2 diabetes mellitus
Vásquez-Muñoz, M., Arce‐Álvarez, A., Álvarez, C., Ramírez‐Campillo, R., Crespo, F., Arias, D., Salazar‐Ardiles, C., Izquierdo, M., & Andrade, D. C. (2022) · Biological Research · doi:10.1186/s40659-022-00406-1 · Cited by 3
Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL
Rao, V. N., Sharma, A., Stebbins, A. S., Buse, J. B., Katona, B. G., Pagidipati, N. J., Holman, R. R., Hernandez, A. F., Mentz, R. J., & Lópes, R. D. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.02.013 · Cited by 3
Self-citationSabirov, I. S., Murkamilov, I. T., & Fomin, V. V. (2021) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2021-10-3-79-89 · Cited by 9
Barre, D. E., & Mizier-Barre, K. A. (2021) · Endocrine Regulations · doi:10.2478/enr-2021-0020 · Cited by 2
“Such atherosclerosis management is important as atherosclerosis causes myocardial infarction and stroke the two major causes of death in T2D patients (Sasaki et al. 1995; Alberti et al. 2007; Sharma et al. 2017).”
BackgroundSharma, A., Wu, J., Xu, H., Hernandez, A. F., Felker, G. M., Al‐Khatib, S. M., Green, J., Matsouaka, R., Fonarow, G. C., Singh, J. P., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012405 · Cited by 2
Self-citationMarx, N., Rydén, L., Brosius, F. C., Ceriello, A., Cheung, M., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0086 · Cited by 2
Self-citationCorrao, S., Orlando, V., Manno, S. B., Cangialosi, V., & Argano, C. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04281-6 · Cited by 1
“Cardiovascular disease (CVD) and its cardiac and cerebrovascular complications represent the leading causes of morbidity and mortality among individuals with diabetes, accounting for more than half of diabetes-related deaths, primarily due to thrombotic events [9, 10].”
Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease
Sharma, A., Razaghizad, A., Stevens, S. R., Lokhnygina, Y. V., Bakris, G. L., Green, J. B., McGuire, D. K., Lópes, R. D., Buse, J. B., Armstrong, P. W., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102598 · Cited by 1
Self-citationSodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
Khan, M. S., & Butler, J. (2019) · Cardiac failure review · doi:10.15420/cfr.2019.06.r1 · Cited by 1
Antidiabetic Phytochemicals and Their Applications in Modern Medicine
Krishna, M. S., & Arun, K. B. (2020) · Springer eBooks · doi:10.1007/978-981-15-1761-7_11 · Cited by 1
A 2-es típusú hazai cukorbetegek többlethalálozásának nem és korcsoport szerinti értékelése
Kiss, Z., Jermendy, G., Rokszin, G., Abonyi‐Tóth, Z., Fábián, I., Kempler, P., & Wittmann, I. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.15 · Cited by 2
Billeter, A. T., & Müller-Stich, B. P. (2019) · Der Chirurg · doi:10.1007/s00104-018-0786-z · Cited by 2
Yazdanpanah, G., Khoshdel, A., Moghaddam, A. D., Tofangchiha, S., Tofighi, E., Bakhshian, M., & Fanaei, S. (2017) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh.4305
New pharmacological strategies in some metabolic endocrine disorder under a toxicological approach
Luisetto, M. (2017) · Annals of Clinical Endocrinology and Metabolism · doi:10.29328/journal.acem.1001006
“HF prevention may represent an avenue to reduce the risk of speci ic CV death subcategories” [15].”
BackgroundEndocrinology and Diabetes in the Elder
Levy, D. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781316823040.027
Recommendations on the Clinical Trial Programme for Diabetes Medicines
Анатольевна, П. И., Petraneva, E. V., & Goryachev, D. V. (2021) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2021-11-2-94-103
Screening Cardiovascular Risk Factors of Diabetes Patients in the Primary Diabetes ClinicsPreprint
An, L., Wang, Y., Cao, C., Chen, T., Zhang, Y., Chen, L., Ren, S., Tang, M., Ma, F., Li, X., et al. (2020) · doi:10.21203/rs.3.rs-111049/v1
Jiang, X.-Y., Chen, Q., Chen, X., Sun, Q., Jing, F., Zhang, H., Xu, J., Li, X., & Guan, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-1733313/v1 · Cited by 1
Samak, M. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9776 · Cited by 1
Rente, A. F. G., Horevicht, C. M., Rocha, D. A. D. F., Mascarenhas, G. M. H. L., Krettli, H. G., Sousa, J. L. D. M., Netto, J. B., & Bertucci, L. N. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p281 · Cited by 1
Billeter, A. T., & Müller-Stich, B. P. (2024) · Springer eBooks · doi:10.1007/978-3-662-58895-6_47
Abbas, D. K., & Issa, A. H. (2025) · Indian Journal of Dental Research · doi:10.4103/ijdr.ijdr_756_23
Wang, Q., Feng, N., & Zhang, Y. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c06159
Antidiabetic medications and arterial thrombotic risk reduction: a narrative review
Santilli, F., Simeone, P., & Liani, R. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04502-y
Metadata
- Authors
- Sharma, A., Green, J. B., Dunning, A., Lokhnygina, Y., Al-Khatib, S. M., Lopes, R. D., Buse, J. B., Lachin, J. M., Van de Werf, F., Armstrong, P. W., Kaufman, K. D., Standl, E., Chan, J. C. N., Distiller, L. A., Scott, R., Peterson, E. D., & Holman, R. R.
- Affiliations
- University of Alberta (CA)
- Duke University (US)
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
- University of North Carolina at Chapel Hill (US)
- George Washington University (US)
- University of Leuven, Leuven, Belgium
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Helmholtz Munich (DE)
- Chinese University of Hong Kong (HK)
- Centre for Diabetes and Endocrinology, Johannesburg, South Africa
- Christchurch Hospital (NZ)
- University of Oxford (GB)
- Corresponding author
- Sharma, Abhinav
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-10-06
- Volume
- 40
- Issue
- 12
- Pages
- 1763-1770
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2763921543
- Cited by
- 80
- References
- 27
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 4 · 2022: 6 · 2021: 16 · 2020: 19 · 2019: 14 · 2018: 4 · 2017: 2
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Merck & Co.
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- type 2 diabetes, atherosclerotic cardiovascular disease, causes of death, cardiovascular mortality, sudden death, acute myocardial infarction, stroke, heart failure, cancer mortality, sitagliptin, TECOS trial, heart failure prevention
- MeSH terms
- Sitagliptin Phosphate, Aged, Cause of Death, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Proportional Hazards Models, Randomized Controlled Trials as Topic, Treatment Outcome, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.